Updates are available Correction dated 2025-03-04
Click to view Correction: https://doi.org/10.1038/s44325-025-00047-9
-
Authors
Rauschendorfer, Philipp
Lenz, Tobias
Nicol, Philipp
Wild, Léa
Beele, Alicia
Sabic, Emina
Klosterman, Grace
Laugwitz, Karl-Ludwig
Jaffer, Farouc A.
Gorpas, Dimitris
Joner, Michael
Ntziachristos, Vasilis
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01, HL150538)
German Center for Cardiovascular Research (FKZ 81Z0600502)
German Center for Cardiovascular Research (FKZ 81X2600526)
Deutsche Forschungsgemeinschaft, CRC (1123, Z1)
- License Information
-
More Information
Article History
Received: 26 April 2024
Accepted: 25 July 2024
First Online: 30 August 2024
Change Date: 4 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44325-025-00047-9
Competing interests
: V.N. is a founder and equity owner of Maurus OY, sThesis GmbH, iThera Medical GmbH, Spear UG and I3 Inc. F.A.J. – sponsored research: Canon, Siemens, Shockwave, Teleflex, Mercator, Boston Scientific, HeartFlow, Neovasc; consultant/speakers fees: Boston Scientific, Siemens, Philips, Biotronik, Mercator, Abiomed, Medtronic; Equity interest: DurVena. Massachusetts General Hospital – licensing arrangements: Terumo, Canon, Spectrawave, for which F.A.J has the right to receive royalties. F.A.J. is a founder and equity owner if I3 Inc. M.J. reports personal fees from Abbott, Alchimedics S.A.S., Astra Zeneca, Biotronik, Medtronic, Recor, Shockwave, TriCares, Veryan, grants and personal fees from Boston Scientific, Cardiac Dimensions, Edwards and grant from Infraredx, outside the submitted work. P.R., T.L., P.N., L.W., A.B., E.S., G.K., K.L., and D.G. declare no competing interest.
